Oxidative stress plays an important role in the pathogenesis of bronchial asthma. An excess production of reactive oxygen species (ROS) and defective endogenous antioxidant defense mechanisms may be present in asthma. Reduced glutathione (GSH) is one of the most important reducing agents against oxidant free radicals. A reducing agent, L-2-oxothiazolidine-4-carboxylic acid (OTC), a prodrug of cysteine, increases intracellular GSH. We have used a mouse model for asthma to determine effects of OTC on allergen-induced bronchial inflammation and airway hyper-responsiveness. The administration of OTC reduced bronchial inflammation and airway hyper-responsiveness. ROS generation in bronchoalveolar lavage fluids was increased by ovalbumin (OVA) inhalation, but this increase was diminished by administration of OTC. The increased IL-4, IL-5, IL-13, and eosinophil cationic protein levels in lungs after OVA inhalation were significantly reduced by the administration of OTC. In addition, the increased expression of ICAM-1, VCAM-1, RANTES, and eotaxin in lungs after OVA inhalation was significantly reduced by the administration of OTC. We also showed that the increased NF-κB levels in nuclear protein extracts of lung tissues at 72 h after OVA inhalation were decreased by the administration of OTC. These findings suggest that OTC may reduce airway inflammation and hyper-responsiveness through regulation of NF-κB activity.
is further provided by the finding of defective endogenous antioxidant capacity in asthmatic patients (4) . Therefore, antioxidant treatment of asthma has long been a subject of therapeutic strategy.
Glutathione (GSH) is synthesized from cysteine and is a vital intracellular and extracellular protective antioxidant against oxidative stress. Alterations in alveolar and lung GSH metabolism are widely recognized as a central feature of many inflammatory lung diseases such as asthma. Cysteine derivatives, N-acetylcysteine, and carbocysteine, which may act as antioxidants, have been shown to exhibit anti-inflammatory and antihyperreactivity in animal models of asthma (5, 6) . However, benefit of these derivatives in asthma is controversial. A thiazolidine derivative, L-2-oxothiazolidine-4-carboxylic acid (OTC) is a prodrug of cysteine that raises the plasma concentrations of cysteine and GSH (7) (8) (9) . This compound is readily transportable into cells and converted to L-cysteine by a ubiquitous intracellular enzyme, 5-oxoprolinase (10) . Several studies have also demonstrated that OTC repletes cellular glutathione stores when glutathione is acutely depleted (11, 12) and is more effective than N-acetylcysteine in repleting intracellular GSH stores (13, 14) . However, there are few data on the influence and the molecular basis of OTC on allergen-induced bronchial inflammation and airway hyper-responsiveness.
In the present study, we used a murine model of asthma to evaluate the effect of OTC on hyperresponsiveness and inflammation of the airways.
METHODS

Animals and experimental protocol
Female BALB/c mice, 8−10 weeks of age and free of murine-specific pathogens, were obtained from the Korean Research Institute of Chemistry Technology (Daejon, Korea), were housed throughout the experiments in a laminar flow cabinet, and were maintained on standard laboratory chow ad libitum. All experimental animals used in this study were under a protocol approved by the Institutional Animal Care and Use Committee of the Chonbuk National University Medical School. Mice were sensitized on days 1 and 14 by intraperitoneal injection of 20 µg ovalbumin (OVA) (Sigma-Aldrich, St. Louis, MO) emulsified in 1 mg of aluminum hydroxide (Pierce Chemical Co., Rockford, IL) in a total volume of 200 µl, as described previously (15) (Fig. 1) . On days 21, 22, and 23 after the initial sensitization, the mice were challenged for 30 min with an aerosol of 3% (w/v) OVA in saline (or with saline as a control) using an ultrasonic nebulizer (NE-U12, Omron, Japan). Bronchoalveolar lavage (BAL) was performed at 72 h after the last challenge. At the time of lavage, the mice (6 mice in each group) were killed with an overdose of sodium pentobarbitone (pentobarbital sodium, 100 mg/kg of body weight, administered intraperitoneally). The chest cavity was exposed to allow for expansion, after which the trachea was carefully intubated and the catheter secured with ligatures. Prewarmed 0.9% NaCl solution was slowly infused into the lungs and withdrawn. The aliquots were pooled and then kept at 4°C. A part of each pool was then centrifuged, and the supernatants were kept at −70°C until use. Total cell numbers were counted with a hemocytometer. Smears of BAL cells were prepared with a cytospin. The smears were stained with Diff-Quik solution (Dade Diagnostics of P. R. Inc. Aguada, PR) in order to examine the cell differentials. Two independent investigators, not associated with this study, counted the cells using a microscope. Approximately 400 cells were counted in each of four different random locations. Interinvestigator variation was <5%. The mean number from the two investigators was used to estimate the cell differentials.
Administration of OTC
OTC solution (40, 80 , or 160 mg/kg body weight/day, Sigma-Aldrich) was freshly prepared as described elsewhere (16) and administered intraperitoneally 4 times at 24 h intervals on days 21−24, beginning 1 h before the first challenge (Fig. 1) .
Measurement of intracellular reactive oxygen species
ROS were measured by a method described previously with modification (17) (18) (19) . BAL fluids were washed with phosphate-buffered saline (PBS). To measure intracellular ROS, cells were incubated for 10 min at room temperature with PBS containing 3.3 µM 2',7'-dichlorofluorescein diacetate (DCFDA) (Molecular Probes, Eugene, OR), to label intracellular ROS. The cells were then immediately observed under fluorescence microscope (Carl Zeiss, Inc., Thornwood, NY) and fluorescence-activated cell sorting (FACS) analysis (Partec, Münster, Germany).
Measurement of cytokines and RANTES
Levels of IL-4, IL-5, IL-13, and RANTES were quantified in the supernatants of BAL fluids by enzyme immunoassays according to the manufacturer's protocol (IL-4 and IL-5; Endogen, Inc., Woburn, MA, IL-13, and RANTES; R&D Systems, Inc., Minneapolis, MN). Sensitivities for IL-4, IL-5, IL-13, and RANTES assays were 5, 5, 1.5, and 2 pg/ml, respectively.
Measurement of eosinophil cationic protein (ECP)
ECP was measured in the supernatants of BAL fluids. Levels of ECP were quantified by fluoroenzymeimmunoassay, according to the manufacturer's protocol (UniCAP ECP; Pharmacia and Upjohn Diagnostics AB, Uppsala, Sweden). Sensitivity for the assay was 2 ng/ml.
Determination of airway responsiveness to methacholine
Airway responsiveness was measured in mice 3 days after the last challenge in an unrestrained conscious state, as described previously (15, 20, 21) . Mice were placed in a barometric plethysmographic chamber (All Medicus Co., Seoul, Korea) and baseline readings were taken and averaged for 3 min. Aerosolized methacholine in increasing concentrations (2.5 to 50 mg/ml) were nebulized through an inlet of the main chamber for 3 min. Readings were taken and averaged for 3 min after each nebulization. Enhanced pause (Penh), calculated as (expiratory time/relaxation time-1) × (peak expiratory flow/peak inspiratory flow), according to the manufacturers' protocol, is a dimensionless value that represents a function of the proportion of maximal expiratory to maximal inspiratory box pressure signals and a function of the timing of expiration. Penh was used as a measure of airway responsiveness to methacholine. Results were expressed as the percentage increase of Penh following challenge with each concentration of methacholine, where the baseline Penh (after saline challenge) was expressed as 100%. Penh values averaged for 3 min after each nebulization were evaluated.
Histology
At 72 h after the last challenge, lungs were removed from the mice after sacrifice. Before the lungs were removed, the lungs and trachea were filled intratracheally with a fixative (0.8% formalin, 4% acetic acid) using a ligature around the trachea. Lung tissues were fixed with 10% (v/v) neutral buffered formalin. The specimens were dehydrated and embedded in paraffin. For histological examination, 4 µm sections of fixed embedded tissues were cut on a Leica model 2165 rotary microtome (Leica, Nussloch, Germany), placed on glass slides, deparaffinized, and stained sequentially with hematoxylin 2 and eosin-Y (Richard-Allan Scientific, Kalamazoo, MI). Inflammation score was graded by three independent investigators who were not associated with this study. The degree of peribronchial and perivascular inflammation was evaluated on a subjective scale of 0 to 3, as described elsewhere (22). A value of 0 was adjudged when no inflammation was detectable, a value of 1 for occasional cuffing with inflammatory cells, a value of 2 for most bronchi or vessels surrounded by thin layer (one to five cells) of inflammatory cells, and a value of 3 when most bronchi or vessels were surrounded by a thick layer (more than five cells) of inflammatory cells.
Western blot analysis
Lung tissues were homogenized in the presence of protease inhibitors to obtain extracts of proteins. Protein concentrations were determined using the Bradford reagent (Bio-Rad, Hercules, CA). Samples (30 µg of protein per lane) were loaded on a 12% SDS-PAGE gel. After electrophoresis at 120 V for 90 min, separated proteins were transferred to polyvinylidene difluoride membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by the wet transfer method (250 mA, 90 min). Nonspecific sites were blocked with 5% nonfat dry milk in TBST buffer (25 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween 20) for 1 h, and the blots were then incubated with antibody against IL-4 (Serotec Ltd., Oxford, United Kingdom), IL-5 (Santa Cruz Biotechnology Inc., Santa Cruz, CA), or IL-13 (R&D Systems, Inc.), overnight at 4°C. Antirabbit horseradish peroxidase conjugated IgG was used to detect binding of antibodies. The membranes were stripped and reblotted with anti-actin antibody (Sigma-Aldrich) to verify equal loading of protein in each lane. The binding of the specific antibodies was visualized by exposing to photographic film after treating with enhanced chemiluminescence system reagents (Amersham Pharmacia Biotech).
Cytosolic and nuclear protein extractions for analysis of NF-κB
Lungs were removed and homogenized in 2 volumes of buffer A (50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 10% glycerol, 0.5 mM DTT, 5 mM MgCl 2 , and 1 mM PMSF) containing protease inhibitor cocktails. These homogenates were centrifuged at 1000 × g for 15 min at 4°C. The supernatant fraction was incubated on ice for 10 min and centrifuged at 100,000 × g for 1 h at 4°C to obtain cytosolic protein extracts. The pellets were washed twice in buffer A and resuspended in buffer B (1.3 M sucrose, 1.0 mM MgCl 2 , and 10 mM potassium phosphate buffer, pH 6.8) and pelleted at 1000 × g for 15 min. The pellets were suspended in buffer B with a final sucrose concentration of 2.2 M and centrifuged at 100,000 × g for 1 h. The resulting nuclear pellets were washed once with a solution containing 0.25 M sucrose, 0.5 mM MgCl 2 , and 20 mM Tris-HCl, pH 7.2, and centrifuged at 1000 × g for 10 min. The pellets were solubilized with a solution containing 50 mM Tris-HCl (pH 7.2), 0.3 M sucrose, 150 mM NaCl, 2 mM EDTA, 20% glycerol, 2% Triton X-100, 2 mM PMSF, and protease inhibitor cocktails. The mixture was kept on ice for 1 h with gentle stirring and centrifuged at 12,000 × g for 30 min. The resulting supernatant was used as soluble nuclear proteins.
For Western analysis, samples (30 µg of protein per lane) were loaded on a 10% SDS-PAGE gel. After electrophoresis at 120 V for 90 min, separated proteins were transferred to polyvinylidene difluoride membranes (Amersham Pharmacia Biotech,) by the wet transfer method (250 mA, 90 min). Nonspecific sites were blocked with 5% nonfat dry milk in TBST buffer (25 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Tween 20) for 1 h, and the blots were incubated with antibody against NF-κB p65 (Upstate Biotech, Lake Placid, NY) overnight at 4°C. Anti-rabbit horseradish peroxidase conjugated IgG was used to detect binding of antibodies. The binding of the specific antibodies was visualized by exposing to photographic film after treating with enhanced chemiluminescence system reagents (Amersham Pharmacia Biotech).
Electrophoretic-mobility-shift assay
Electrophoretic-mobility-shift assay was performed as described previously (23). As a probe for the gel retardation assay, an oligonucleotide containing the Igκ-chain binding site (κB, 5-CCGGTTAACAGAGGGG-GCTTTCCGAG-3) was synthesized. The two complementary strands were annealed and labeled with [α-
32 P]dCTP. Labeled oligonucleotides (10,000 cpm), 10 µg of nuclear extracts, and binding buffer (10 mM Tris-HC1 (pH 7.6), 500 mM KCl, 10 mM EDTA, 50% glycerol, 100 ng of poly (dIdC), and 1 mM dithiothreitol) were incubated for 30 min at room temperature in a final volume of 20 µl. The reaction mixture was analyzed by electrophoresis on a 5% polyacrylamide gel in Tris-borate/EDTA buffer. Specific binding was controlled by competition with a 50-fold excess of cold κB or cAMP response element (CRE) oligonucleotide. For supershift assay, 1 µg of specific supershifting antibodies against p50 or p65 components of NF-κB (Santa Cruz Biotechnology, Inc.) were incubated with the nuclear extract on ice for 1 h before the addition of labeled oligonucleotide to the binding reaction.
RNA isolation and RT-PCR
Total RNA from lung tissues was isolated using a rapid extraction method (TRI-Reagent) as described previously (24). RNA was quantified by measuring absorption at 260 nm and was stored at −80°C before use. Total RNA (4 µg) was reverse-transcribed to cDNA in a buffer containing 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 5 mM MgCl 2 , 10 mM DTT; 0.5 µg random hexanucleotide primers, 2.5 mM dNTP, 40 units RNase inhibitor, and 50 units/µl SuperScript II RT (Invitrogen, Carlsbad, CA), in a final volume of 20 µl. This mixture was incubated for 50 min at 42°C and was finally digested with 2 units/µl E. coli RNase H for 20 min at 37°C. The first-strand cDNAs were used for PCR amplification of ICAM-1, VCAM-1, RANTES, eotaxin, or the housekeeping gene, GAPDH. PCR amplification was performed by mixing 3 µl of the RT reaction mixture with 47 µl of buffer containing 2.5 U of Taq DNA polymerase (Promega, Madison, WI) and 30 pmol of specific primer pairs for mouse cDNA of ICAM-1, VCAM-1, RANTES, eotaxin, or GAPDH, designed from published mouse gene sequences. The primers used were as follows: ICAM-1 (predicted length 624 bp) sense: 5′-CATCGGGGTGGTGAAGTCTGT-3′, antisense: 5′-TGTGGGGGAAG-TGTGGTC-3′; VCAM-1 (predicted length 518 bp) sense: 5′-CAAGGGTGACCAGC-TCATGAA-3′, antisense: 5′-TGTGCAGCCACCTGAGATCC-3′; RANTES (predicted length 294 bp) sense: 5′-GGTACCATGAAGATCTCTGCA-3′, antisense: 5′-AAACCC-TCTATCCTAGCTCAT-3′; eotaxin (predicted length 262 bp) sense: 5′-AGAGGCTGA-GATCCAAGCAG-3′, antisense: 5′-CAGATCTCTTTGCCCAACCT-3′, and GAPDH (predicted length 609 bp) sense: 5′-GCCATCAACGACCCCTTCATTGAC-3′, antisense: 5′-ACGGAAGGCCATGCCAGTGAGCTT-3′. PCR reactions were performed in a thermocycler (GeneAmp ® PCR System 2400, Foster City, CA) using the following reaction conditions; after an initial incubation for 2 min at 95°C, samples were subjected to 35 cycles of 1 min at 94°C, 2 min at 54°C (GAPDH), 55°C (eotaxin), 56°C (RANTES), 60°C (ICAM-1), or 63°C (VCAM-1) and 1 min at 72°C. A final extension step at 72°C for 10 min was performed. The RT-PCR products were electrophoretically fractioned on 2% agarose gels stained with ethidium bromide. DNA bands were visualized after exposure to UV light.
Densitometric analysis and statistics
All immunoreactive and phosphorylation signals were analyzed by densitometric scanning (LAS-3000; Fuji Film, Tokyo, Japan). Data were expressed as mean ± SEM. Statistical comparisons were performed using one-way ANOVA followed by the Fisher's test. Significant differences between groups were determined using the unpaired Student's t test. Statistical significance was set at P < 0.05.
RESULTS
Effect of OTC on ROS generation in BAL fluids
ROS generation in BAL fluids was increased significantly at 72 h after OVA inhalation compared with the levels after saline inhalation (Fig. 2) . The increased ROS generation was significantly reduced by the administration of OTC.
Effect of OTC on cellular changes in BAL fluids
Numbers of total cells, eosinophils, lymphocytes, and neutrophils in BAL fluids were increased significantly at 72 h after OVA inhalation compared with the numbers after saline inhalation (Fig. 3A) . The increased numbers of these cells were significantly reduced by the administration of OTC.
Effect of OTC on pathological changes of OVA-induced asthma
Histological analyses revealed typical pathologic features of asthma in the OVA-exposed mice. Numerous inflammatory cells, including eosinophils infiltrated around the bronchioles (Fig. 3C) as compared with the control (Fig. 3B ). Mice treated with OTC ( Fig. 3D-F) showed marked reductions in the infiltration of inflammatory cells in the peribronchiolar and perivascular regions. The scores of peribronchial, perivascular, and total lung inflammation were increased significantly at 72 h after OVA inhalation compared with the scores after saline inhalation (Fig.  3G) . The increased peribronchial, perivascular, and total lung inflammation were significantly reduced by the administration of OTC. These results suggest that OTC inhibits antigen-induced inflammation in the lungs, including the influx of eosinophils.
Effect of OTC on NF-κB expression in lung tissues of OVA-sensitized and OVA-challenged mice
Western blot analysis revealed that levels of NF-κB p65 protein in nuclear protein extracts from lung tissues were increased at 72 h after OVA inhalation compared with the levels in the control mice (Fig. 4A) . The increased NF-κB p65 levels in nuclear protein extracts from lung tissues at 72 h after OVA inhalation were decreased by the administration of OTC. In contrast, levels of NF-κB p65 protein in cytosolic protein extracts from lung tissues were decreased at 72 h after OVA inhalation compared with the levels in the control mice. The decreased NF-κB p65 levels in cytosolic protein extracts from lung tissues at 72 h after OVA inhalation were increased by the administration of OTC.
Electrophoretic-mobility-shift assay revealed that NF-κB-DNA binding in nuclear extracts from lung tissues was increased at 72 h after OVA inhalation compared with the levels in the control mice (Fig. 4B) . The increased NF-κB-DNA binding in nuclear extracts from lung tissues at 72 h after OVA inhalation was decreased by the administration of OTC. Supershift assay confirmed the presence of p50 and p65 subunits of NF-κB.
Effect of OTC on levels of IL-4, IL-5, and IL-13 in lung tissues and BAL fluids of OVAsensitized and -challenged mice
Western blot analysis revealed that levels of IL-4, IL-5, and IL-13 protein in lung tissues were increased significantly at 72 h after OVA inhalation compared with the levels after saline inhalation (Fig. 5A) . The increased levels of these cytokines were significantly reduced by the administration of OTC. Consistent with the results obtained from the Western blot analysis, enzyme immunoassays revealed that levels of IL-4, IL-5, and IL-13 in BAL fluids were also increased significantly at 72 h after OVA inhalation compared with the levels after saline inhalation (Fig. 5B) . The increased levels of these cytokines were also significantly reduced by the administration of OTC.
Effect of OTC on expression of ICAM-1, VCAM-1, RANTES, and eotaxin mRNA and protein levels in lung tissues and BAL fluids of OVA-sensitized and -challenged mice RT PCR analysis revealed that expression of ICAM-1, VCAM-1, RANTES, and eotaxin mRNA in lung tissues was increased significantly at 72 h after OVA inhalation compared with the levels after saline inhalation ( Fig. 6A, B; Fig. 7A, B; and Fig. 8A, B) . The increased mRNA expression of these adhesion molecules and chemokines was decreased by the administration of OTC. Western blot analysis revealed that levels of ICAM-1, VCAM-1, and eotaxin protein in the lung tissues were increased significantly at 72 h after OVA inhalation compared with the levels after saline inhalation (Fig. 6C, D and Fig. 8C, D) . The increased levels of ICAM-1, VCAM-1, and eotaxin protein were significantly reduced by the administration of OTC. In addition, enzyme immunoassays revealed that levels of RANTES in BAL fluids were also increased significantly at 72 h after OVA inhalation compared with the levels after saline inhalation (Fig. 7C) . The increased RANTES levels were significantly reduced by the administration of OTC.
Effect of OTC on levels ECP in BAL fluids of OVA-sensitized and -challenged mice
Fluoroenzyme immunoassays revealed that levels of ECP in BAL fluids were increased significantly at 72 h after OVA inhalation compared with the levels after saline inhalation (Fig.  9) . The increased ECP levels were significantly reduced by the administration of OTC.
Effect of OTC on airway hyper-responsiveness
Airway responsiveness was assessed as a percent increase of Penh in response to increasing doses of methacholine. In OVA-sensitized and -challenged mice, the dose-response curve of percent Penh shifted to the left compared with that of control mice (Fig. 10) . In addition, the percent Penh produced by methacholine administration (at doses from 2.5 mg/ml to 50 mg/ml) increased significantly in the OVA-sensitized and -challenged mice compared with the controls. OVA-sensitized and -challenged mice treated with OTC showed a dose-response curve of percent Penh that shifted to the right compared with that of untreated mice. The shift was dosedependent. These results indicate that OTC treatment reduces OVA-induced airway hyperresponsiveness.
DISCUSSION
Oxidative stress plays an important role in the pathogenesis of bronchial asthma (4). Our present study with the OVA-induced model of asthma has revealed that ROS production in cells from BAL fluids and administration of a prodrug of cysteine, OTC, which is known as a precursor of GSH biosynthesis, reduces the eosinophilic inflammation and airway hyper-responsiveness. Our results also indicate that ROS up-regulate a transcription factor NF-κB activity and that OTC down-regulates NF-κB activity.
ROS released by eosinophils and other leukocytes infiltrating the airways play an important role in the airway tissue injury observed in asthma (4) . Previous reports have shown that the release of ROS is increased in the airways of OVA-challenged animals (25, 26). In this study, we have found that generation of ROS in BAL fluids is significantly increased after allergen challenge in OVA-induced asthma model and that administration of OTC reduced the generation of ROS. Although the lung has a well-developed antioxidant system (27, 28), overproduction of ROS or depression of the protective system results in epithelial cell damage, cell shedding, and bronchial hyper-reactivity (29, 30). Studies with animal models have indicated that ROS contribute to airway hyper-responsiveness by increasing vagal tone resulting from damage of oxidant sensitive β-adrenergic receptors as well as decreasing mucociliary clearance (31, 32). These findings suggest that ROS induce and maintain pathogenesis of asthma.
The molecular basis of ROS-mediated induction of asthma has not been clearly defined. A recent study has indicated that development of oxidant/antioxidant imbalance in asthma leads to activation of redox-sensitive transcription factor NF-κB (33) . NF-κB is present in most cell types and is known to play a critical role in immune and inflammatory responses, including asthma (34) (35) (36) (37) (38) (39) . Consistent with these observations, NF-κB protein level in nuclear protein extracts from lung tissues is substantially increased in the OVA-induced model of asthma used for the present study. It is known that activation of this transcription factor induces a variety of inflammatory genes that are abnormally expressed in asthma. These genes include cytokines (e.g., IL-4, IL-5, IL-9, IL-15, and TNF-α), chemokines (e.g., RANTES, eotaxin, and monocyte chemotactic protein-3), and adhesion molecules (e.g., ICAM-1 and VCAM-1) (24, 39-41). We have also assessed whether these genes are up-regulated in the OVA-induced asthma model. As expected, expression of adhesion molecules (ICAM-1 and VCAM-1), chemokines (RANTES and eotaxin), and cytokines (IL-4, IL-5, and IL-13) was increased significantly after allergen challenge in a murine model of asthma. Administration of OTC results in significant reduction of NF-κB translocation into nucleus and of expression of these adhesion molecules, chemokines, and cytokines. These results indicate that OTC inhibits NF-κB activity by preventing translocation of this transcription factor into a nucleus that is induced by ROS. ROS have been directly implicated as second messengers in the activation of NF-κB, based upon the ability of oxidants to activate NF-κB by oxidation of its cysteine-SH group or by ubiquitination and proteolysis (42) (43) (44) . Inhibitory κB (IκB) has 5−7 conserved domains known as ankylin repeats, each consisting of around 30 amino acids, forming a unit that is able to interact with NF-κB subunits, thus masking the nuclear localization signals and preventing activation of NF-κB and its translocation to the nucleus (44, 45) . Antioxidants have been known to inhibit NF-κB activation by preventing IκB degradation in response to various stimuli (46) (47) (48) (49) (50) . Therefore, we suggest that OTC inhibits NF-κB signal transduction pathway by decreasing NF-κB binding activity to the promoter regions of a large variety of genes that are considered to be involved in airway inflammation in asthma.
A significant amount of data showing an increase of oxidative stress in asthma and indicating a potential role of oxidant in pathogenesis of the diseases has been accumulated over years. On the basis of on these observations and to find a potential therapeutic strategy treating asthma, we have administered an antioxidant agent OTC to allergen-challenged mice. Administration of OTC results in a significant reduction of all pathophysiological symptoms examined. Our study provides evidence that oxidative stress is one of the important determinants of asthma and that antioxidant treatment such as administration of OTC, which is transportable into cells, may be a recommendable therapeutic strategy. . Effect of OTC on NF-κB expression in nuclear and cytosolic protein extracts from lung tissues of OVAsensitized and -challenged mice. A) NF-κB p65 expression in nuclear (Nuc) and cytosolic (Cyt) protein extracts from lung tissues. B) Representative electrophoretic-mobility-shift assay of nuclear extracts from lung tissues. NF-κB expression was measured at 72 h after the last challenge in saline-inhaled mice administered saline (SAL+SAL), OVAinhaled mice administered saline (OVA+SAL), OVA-inhaled mice administered drug vehicle (OVA+VEH), OVA-inhaled mice administered OTC 80 mg/kg (OVA+OTC 80), and OVA-inhaled mice administered OTC 160 mg/kg (OVA+OTC 160). Nuclear extracts were incubated with an α-32 P-labeled κB oligonucleotide, and the samples were electrophoresed on a 5% polyacrylamide gel. A 50-fold excess of cold κB or cAMP response element (CRE) oligonucleotide was added as a competitor. Supershift assay was conducted with anti-p50, anti-p65, or control rabbit antibody. Results were similar in six independent experiments. sensitized and -challenged mice. A) RT-PCR of RANTES. Sampling was performed at 72 h after the last challenge in saline-inhaled mice administered saline (SAL+SAL), OVA-inhaled mice administered saline (OVA+SAL), OVA-inhaled mice administered drug vehicle (OVA+VEH), OVA-inhaled mice administered OTC 80 mg/kg (OVA+OTC 80), and OVA-inhaled mice administered OTC 160 mg/kg (OVA+OTC 160). B) Densitometric analyses are presented as the relative ratio of RANTES mRNA to GAPDH mRNA. The relative ratio of each molecule mRNA in the lung tissues of SAL+SAL is arbitrarily presented as 1. C) Enzyme immunoassay of RANTES. Data represent mean ± SEM from 6 independent experiments. # P < 0.05 vs. SAL+SAL; *P < 0.05 vs. OVA+SAL. Airway responsiveness to aerosolized methacholine was measured in unrestrained, conscious mice. Mice were placed into the main chamber and were nebulized first with saline, then with increasing doses (2.5 to 50 mg/ml) of methacholine for 3 min for each nebulization. Readings of breathing parameters were taken for 3 min after each nebulization during which Penh values were determined. Data represent mean ± SEM from 6 independent experiments. # P < 0.05 vs. SAL+SAL; *P < 0.05 vs. OVA+SAL.
